Targeting reactive astrogliosis by novel biotechnological strategies

Biotechnology Advances

Volumn 30, Issue 1, 2012, Pages 261-271

  Colangelo, Anna Maria ^b   Cirillo, Giovanni ^a   Lavitrano, Maria Luisa ^b   Alberghina, Lilia ^b   Papa, Michele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Nerve injury; Neuro glial network; NGF like peptide; Reactive astrocytosis; Synaptic homeostasis

Indexed keywords

ANIMAL MODEL; ASTROGLIOSIS; BRAIN CIRCUITS; BRAIN FUNCTIONS; BRAIN INJURY; CENTRAL NERVOUS SYSTEMS; CLINICAL MANAGEMENT; GLIAL CELLS; MICROGLIAL CELLS; NERVE INJURIES; NEURODEGENERATION; NEURODEGENERATIVE DISORDERS; NEUROPROTECTION; NEUROTROPHINS; REACTIVE ASTROCYTOSIS; SYNAPTIC HOMEOSTASIS; SYNAPTIC PLASTICITY;

BRAIN MODELS; CELLS; METABOLISM; NETWORKS (CIRCUITS); NEURONS; PHYSIOLOGY;

NEURODEGENERATIVE DISEASES;

NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT;

BIODEGRADATION; BIOTECHNOLOGY; BRAIN; CELL ORGANELLE; DEVELOPMENTAL BIOLOGY; HOMEOSTASIS; MATURATION; METABOLISM; NERVOUS SYSTEM; NEUROLOGY; NUMERICAL MODEL; PATHOLOGY; PHENOTYPIC PLASTICITY;

ANIMAL; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; DEGENERATIVE DISEASE; DISEASE MODEL; GLIA; GLIOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; NERVE CELL PLASTICITY; PATHOLOGY; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; GLIOSIS; HUMANS; IMMUNOHISTOCHEMISTRY; MODELS, BIOLOGICAL; MODELS, MOLECULAR; NERVE GROWTH FACTOR; NEURODEGENERATIVE DISEASES; NEUROGLIA; NEURONAL PLASTICITY; NEUROPROTECTIVE AGENTS;

ANIMALIA;

EID: 84855731719     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2011.06.016     Document Type: Review

References (149)

1. Alberghina L., Colangelo A.M. The modular systems biology approach to investigate the control of apoptosis in Alzheimer's disease neurodegeneration. BMC Neurosci 2006, 7(Suppl 1):S2. Oct 30.
2. Allegrini P., Fronzoni L., Pirino D. The influence of the astrocyte field on neuronal dynamics and synchronization. J Biol Phys 2009, 35:413-423.
3. Aloe L., Tirassa P., Lambiase A. The topical application of nerve growth factor as a pharmacological tool for human corneal and skin ulcers. Pharmacol Res 2008, 57:253-258.
4. Al-Shawi R., Hafner A., Chun S., Raza S., Crutcher K., Thrasivoulou C., et al. ProNGF, sortilin, and age-related neurodegeneration. Ann NY Acad Sci 2007, 1119:208-215.
5. Apfel S.C. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold?. Int Rev Neurobiol 2002, 50:393-413.
6. Bagnis A., Papadia M., Scotto R., Traverso C.E. Current and emerging medical therapies in the treatment of glaucoma. Expert Opin Emerg Drugs 2011, 16:293-307.
7. Bai Y., Dergham P., Nedev H., Xu J., Galan A., Rivera J.C., et al. Chronic and acute models of retinal neurodegeneration TrkA activity are neuroprotective whereas p75NTR activity is neurotoxic through a paracrine mechanism. J Biol Chem 2010, 285:39392-39400.
8. Bajramovic J.J. Regulation of innate immune responses in the central nervous system. CNS Neurol Disord Drug Targets 2011, 10:4-24.
9. Bal-Price A., Brown G.C. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 2001, 21:6480-6491.
10. Beattie M.S., Harrington A.W., Lee R., Kim J.Y., Boyce S.L., Longo F.M., et al. ProNGF induces p75-mediated death of oligodendrocytes following spinal cord injury. Neuron 2002, 36:375-386.
11. Benarroch E.E. Neuron-astrocyte interactions: partnership for normal function and disease in the central nervous system. Mayo Clin Proc 2005, 80:1326-1338.
12. Bentley C.A., Lee K.F. p75 is important for axon growth and Schwann cell migration during development. J Neurosci 2000, 20:7706-7715.
13. Bolaños J.P., Almeida A., Moncada S. Glycolysis: a bioenergetic or a survival pathway?. Trends Biochem Sci 2010, 35:145-149.
14. Borlongan C.V., Koutouzis T.K., Sanberg P.R. 3-Nitropropionic acid animal model and Huntington's disease. Neurosci Biobehav Rev 1997, 21:289-293.
15. Bringmann A., Iandiev I., Pannicke T., Wurm A., Hollborn M., Wiedemann P., et al. Cellular signaling and factors involved in Müller cell gliosis: neuroprotective and detrimental effects. Prog Retin Eye Res 2009, 28:423-451.
16. Brouillet E., Jacquard C., Bizat N., Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 2005, 95:1521-1540.
17. Bruno M.A., Cuello A.C. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc Natl Acad Sci USA 2006, 103:6735-6740.
18. Bruno M.A., Clarke P.B., Seltzer A., Quirion R., Burgess K., Cuello A.C., et al. Long-lasting rescue of age-associated deficits in cognition and the CNS cholinergic phenotype by a partial agonist peptidomimetic ligand of TrkA. J Neurosci 2004, 24:8009-8018.
19. Calissano P., Matrone C., Amadoro G. Nerve growth factor as a paradigm of neurotrophins related to Alzheimer's disease. Dev Neurobiol 2010, 70:372-383.
20. Casaccia-Bonnefil P., Carter B.D., Dobrowsky R.T., Chao M.V. Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75. Nature 1996, 383:716-719.
21. Cavaliere C., Cirillo G., Bianco M.R., Rossi F., De Novellis V., Maione S., et al. Gliosis alters expression and uptake of spinal glial amino acid transporters in a mouse neuropathic pain model. NGB 2007, 2:141-153.
22. Cazorla M., Prémont J., Mann A., Girard N., Kellendonk C., Rognan D. Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J Clin Invest 2011, 121:1846-1857.
23. Chao M.V. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 2003, 4:299-309.
24. Chao M.V., Bothwell M. Neurotrophins: to cleave or not to cleave. Neuron 2002, 33:9-12.
25. Chao M.V., Rajagopal R., Lee F.S. Neurotrophin signalling in health and disease. Clin Sci 2006, 110:167-173.
26. Chaudhry F.A., Lehre K.P., van Lookeren Campagne M., Ottersen O.P., Danbolt N.C., Storm-Mathisen J. Glutamate transporters in glial plasma membranes: highly differentiated localizations revealed by quantitative ultrastructural immunocytochemistry. Neuron 1995, 15:711-720.
27. Chen L.W., Yung K.K.L., Chan Y.S., Shum D.K.Y., Bolam J.P. The proNGF-p75NTR-sortilin signalling complex as new target for the therapeutic treatment of Parkinson's disease. CNS Neurol Disord Drug Targets 2008, 7:512-523.
28. Chung Y.C., Ko H.W., Bok E., Park E.S., Huh S.H., Nam J.H., et al. The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Rep 2010, 43:225-232.
29. Cirillo G., Cavaliere C., Bianco M.R., De Simone A., Colangelo A.M., Sellitti S., et al. Intrathecal NGF administration reduces reactive astrocytosis and changes neurotrophin receptors expression pattern in a rat model of neuropathic pain. Cell Mol Neurobiol 2010, 30:51-62.
30. Cirillo G., Maggio N., Bianco M.R., Vollono C., Sellitti S., Papa M. Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats. Neurochem Int 2010, 56:152-160.
31. Cirillo G., Bianco M.R., Colangelo A.M., Cavaliere C., Daniele de L., Zaccaro L., et al. Reactive astrocytosis-induced perturbation of synaptic homeostasis is restored by nerve growth factor. Neurobiol Dis 2011, 41:630-639.
32. Colafrancesco V., Parisi V., Sposato V., Rossi S., Russo M.A., Coassin M., et al. Ocular application of nerve growth factor protects degenerating retinal ganglion cells in a rat model of glaucoma. J Glaucoma 2011, 20:100-108.
33. Colangelo A.M., Johnson P.F., Mocchetti I. Beta-adrenergic receptor-induced activation of nerve growth factor gene transcription in rat cerebral cortex involves CCAAT/enhancer-binding protein delta. Proc Natl Acad Sci USA 1998, 95:10920-10925.
34. Colangelo A.M., Bianco M.R., Vitagliano L., Cavaliere C., Cirillo G., De Gioia L., et al. A new nerve growth factor-mimetic peptide active on neuropathic pain in rats. J Neurosci 2008, 28:2698-2709.
35. Cosgaya J.M., Chan J.R., Shooter E.M. The neurotrophin receptor p75NTR as a positive modulator of myelination. Science 2002, 298:1245-1248.
36. Cragnolini A.B., Friedman W.J. The function of p75NTR in glia. Trends Neurosci 2008, 31:99-104.
37. Cragnolini A.B., Huang Y., Gokina P., Friedman W.J. Nerve growth factor attenuates proliferation of astrocytes via the p75 neurotrophin receptor. Glia 2009, 57:1386-1392.
38. Cuello A.C., Bruno M.A. The failure in NGF maturation and its increased degradation as the probable cause for the vulnerability of cholinergic neurons in Alzheimer's disease. Neurochem Res 2007, 32:1041-1045.
39. Danbolt N.C. Glutamate uptake. Prog Neurobiol 2001, 65:1-105.
40. Davalos D., Grutzendler J., Yang G., Kim J.V., Zuo Y., Jung S., et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005, 8:752-758.
41. de Melo Reis R.A., Ventura A.L., Schitine C.S., de Mello M.C., de Mello F.G. Müller glia as an active compartment modulating nervous activity in the vertebrate retina: neurotransmitters and trophic factors. Neurochem Res 2008, 33:1466-1474.
42. Domeniconi M., Hempstead B.L., Chao M.V. Pro-NGF secreted by astrocytes promotes motor neuron cell death. Mol Cell Neurosci 2007, 34:271-279.
43. Dun Y., Mysona B., Van Ells T., Amarnath L., Ola M.S., Ganapathy V., et al. Expression of the cystine-glutamate exchanger (xc-) in retinal ganglion cells and regulation by nitric oxide and oxidative stress. Cell Tissue Res 2006, 324:189-202.
44. Fahnestock M., Michalski B., Xu B., Coughlin M.D. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci 2001, 18:210-220.
45. Faideau M., Kim J., Cormier K., Gilmore R., Welch M., Auregan G., et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum Mol Genet 2010, 19:3053-3067.
46. Fellin T., Carmignoto G. Neurone-to-astrocyte signalling in the brain represents a distinct multifunctional unit. J Physiol 2004, 559:3-15.
47. Festoff B.W., Ameenuddin S., Arnold P.M., Wong A., Santacruz K.S., Citron B.A. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem 2006, 97:1314-1326.
48. Friedman W.J. Neurotrophins induce death of hippocampal neurons via the p75 receptor. J Neurosci 2000, 20:6340-6346.
49. Friedman W.J., Thakur S., Seidman L., Rabson A.B. Regulation of nerve growth factor mRNA by interleukin-1 in rat hippocampal astrocytes is mediated by NFkappaB. J Biol Chem 1996, 271:31115-31120.
50. Galve-Roperh I., Malpartida J.M., Haro A., Brachet P., Díaz-Laviada I. Regulation of nerve growth factor secretion and mRNA expression by bacterial lipopolysaccharide in primary cultures of rat astrocytes. J Neurosci Res 1997, 49:569-575.
51. Giovannoni R., Maggio N., Bianco M.R., Cavaliere C., Cirillo G., Lavitrano M., et al. Reactive astrocytosis and glial glutamate transporter clustering are early changes in a spinocerebellar ataxia type 1 transgenic mouse model. Neuron Glia Biol 2007, 3:335-351.
52. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
53. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., et al. Study group. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007, 6:1045-1053.
54. Gray B.C., Skipp P., O'Connor V.M., Perry V.H. Increased expression of glial fibrillary acidic protein fragments and mu-calpain activation within the hippocampus of prion-infected mice. Biochem Soc Trans 2006, 34:51-54.
55. Griffin W.S., Liu L., Li Y., Mrak R.E., Barger S.W. Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation 2006, 3:5.
56. Hanisch U.K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007, 10:1387-1394.
57. Harrington A.W., Leiner B., Blechschmitt C., Arevalo J.C., Lee R., Mörl K., et al. Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. Proc Natl Acad Sci USA 2004, 16:6226-6230.
58. Hashizume H., DeLeo J.A., Colburn R.W., Weinstein J.N. Spinal glial activation and cytokine expression after lumbar root injury in the rat. Spine 2000, 25:1206-1217.
59. Haydon P.G. Glia: listening and talking to the synapse. Nat Rev Neurosci 2001, 2:185-193.
60. Heales S.J., Lam A.A., Duncan A.J., Land J.M. Neurodegeneration or neuroprotection: the pivotal role of astrocytes. Neurochem Res 2004, 29:513-519.
61. Heneka M.T., Rodriguez J.J., Verkhratsky A. Neuroglia in neurodegeneration. Brain Res Rev 2010, 63:189-211.
62. Herrero-Mendez A., Almeida A., Fernández E., Maestre C., Moncada S., Bolaños J.P. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat Cell Biol 2009, 11:747-752.
63. Hickey M.A., Kosmalska A., Enayati J., Cohen R., Zeitlin S., Levine M.S., et al. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience 2008, 157:280-295.
64. Hirase H. A multi-photon window onto neuronalglial-vascular communication. Trends Neurosci 2005, 28:217-219.
65. Jansen P., Giehl K., Nyengaard J.R., Teng K., Lioubinski O., Sjoegaard S.S., et al. Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury. Nat Neurosci 2007, 10:1449-1457.
66. Ji R.R., Strichartz G. Cell signaling and the genesis of neuropathic pain. Science STKE 2004, reE14.
67. Keller A.F., Gravel M., Kriz J. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp Neurol 2011, 228(1):69-79.
68. Knight R.A., Verkhratsky A. Neurodegenerative diseases: failures in brain connectivity?. Cell Death Differ 2010, 17:1069-1070.
69. Kofuji P., Newman E.A. Potassium buffering in the central nervous system. Neuroscience 2004, 129:1045-1056.
70. Koliatsos V.E., Clatterbuck R.E., Nauta H.J.W., Knusel B., Burton L.E., Hefti F.F., et al. Human Nerve Growth Factor prevents degeneration of basal forebrain cholinergic neurons in primates. Ann Neurol 1991, 30:831-840.
71. Kuang X., Scofield V.L., Yan M., Stoica G., Liu N., Wong P.K. Attenuation of oxidative stress, inflammation and apoptosis by minocycline prevents retrovirus-induced neurodegeneration in mice. Brain Res 2009, 1286:174-184.
72. Kuczewski N., Porcher C., Gaiarsa J.L. Activity-dependent dendritic secretion of brain-derived neurotrophic factor modulates synaptic plasticity. Eur J Neurosci 2010, 32:1239-1244.
73. Lambiase A., Mantelli F., Bonini S. Nerve growth factor eye drops to treat glaucoma. Drug News Perspect 2010, 23:361-367.
74. Landles C., Bates G.P. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep 2004, 5:958-963.
75. Lebrun-Julien F., Bertrand M.J., De Backer O., Stellwagen D., Morales C.R., Di Polo A., et al. ProNGF induces TNFalpha-dependent death of retinal ganglion cells through a p75NTR non-cell-autonomous signaling pathway. Proc Natl Acad Sci USA 2010, 107:3817-3822.
76. Lee Y.B., Du S., Rhim H., Lee E.B., Markelonis G.J., Oh T.H. Rapid increase in immunoreactivity to GFAP in astrocytes in vitro induced by acidic pH is mediated by calcium influx and calpain I. Brain Res 2000, 864:220-229.
77. Lee R., Kermani P., Teng K.K., Hempstead B.L. Regulation of cell survival by secreted proneurotrophins. Science 2001, 294:1945-1958.
78. Lehre K.P., Levy L.M., Ottersen O.P., Storm-Mathisen J., Danbolt N.C. Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. J Neurosci 1995, 15:1835-1853.
79. Levi-Montalcini R. Effects of mouse tumor transplantation on the nervous system. Ann NY Acad Sci 1952, 55:330-344.
80. Lewerenz J., Klein M., Methner A. Cooperative action of glutamate transporters and cystine/glutamate antiporter system Xc- protects from oxidative glutamate toxicity. J Neurochem 2006, 98:916-925.
81. Li Z., Hogan E.L., Banik N.L. Role of calpain in spinal cord injury: increased calpain immunoreactivity in rat spinal cord after impact trauma. Neurochem Res 1996, 21:441-448.
82. Lievens J.C., Salin P., Had-Aissouni L., Mahy N., Kerkerian-Le G.L. Differential effects of corticostriatal and thalamostriatal deafferentation on expression of the glutamate transporter GLT1 in the rat striatum. J Neurochem 2000, 74:909-919.
83. Lobsiger C.S., Cleveland D.W. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci 2007, 10:1355-1360.
84. Loiola E.C., Ventura A.L. Release of ATP from avian Müller glia cells in culture. Neurochem Int 2011, 58:414-422.
85. Lu B., Pang P.T., Woo N.H. The yin and yang of neurotrophin action. Nat Rev Neurosci 2005, 6:603-614.
86. Machado-Vieira R., Manji H.K., Zarate C.A. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009, 15:525-539.
87. Magistretti P.J. Neuron-glia metabolic coupling and plasticity. J Exp Biol 2006, 209:2304-2311.
88. Maragakis N.J., Rothstein J.D. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2006, 2:679-689.
89. Masoudi R., Ioannou M.S., Coughlin M.D., Pagadala P., Neet K.E., Clewes O., et al. Biological activity of Nerve Growth Factor precursor is dependent upon relative levels of its receptors. J Biol Chem 2009, 284:18424-18433.
90. Massa S.M., Xie Y., Yang T., Harrington A.W., Kim M.L., Yoon S.O., et al. Small, nonpeptide p75NTR ligands induce survival signaling and inhibit proNGF-induced death. J Neurosci 2006, 26:5288-5300.
91. Massa S.M., Yang T., Xie Y., Shi J., Bilgen M., Joyce J.N., et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest 2010, 120:1774-1785.
92. McMahon S.B., Cafferty W.B., Marchand F. Immune and glial cell factors as pain mediators and modulators. Exp Neurol 2005, 192:444-462.
93. Mennerick S., Shen W., Xu W., Benz A., Tanaka K., Shimamoto K., et al. Substrate turnover by transporters curtails synaptic glutamate transients. J Neurosci 1999, 19:9242-9251.
94. Milton I.D., Banner S.J., Ince P.G., Piggott N.H., Fray A.E., Thatcher N., et al. Expression of the glial glutamate transporter EAAT2 in the human CNS: an immunohistochemical study. Brain Res Mol Brain Res 1997, 52:17-31.
95. Mocchetti I., Colangelo A.M. Transcriptional regulation of NGF in the central nervous system. Neurobiology of the neurotrophins 2001, 631-654. F.P. Graham Publishing Co. I. Mocchetti (Ed.).
96. Molina-Holgado F., Doherty P., Williams G. Tandem repeat peptide strategy for the design of neurotrophic factor mimetics. CNS Neurol Disord Drug Targets 2008, 7:110-119.
97. Monteggia L.M. Toward neurotrophin-based therapeutics. Am J Psychiatry 2011, 168:114-116.
98. Mrak R.E., Griffin W.S. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 2005, 26:349-354.
99. Musholt K., Cirillo G., Cavaliere C., Bianco M.R., Bock J., Helmeke C., et al. Neonatal separation stress reduces glial fibrillary acidic protein and S100beta-immunoreactive astrocytes in the rat medial precentral cortex. Dev Neurobiol 2009, 69:203-211.
100. Mysona B., Dun Y., Duplantier J., Ganapathy V., Smith S.B. Effects of hyperglycemia and oxidative stress on the glutamate transporters GLAST and system xc- in mouse retinal Müller glial cells. Cell Tissue Res 2009, 335:477-488.
101. Nagahara A.H., Merrill D.A., Coppola G., Tsukada S., Schroeder B.E., Shaked G.M., et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009, 15:331-337.
102. Narita M., Miyatake M., Narita M., Shibasaki M., Shindo K., Nakamura A., et al. Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology 2006, 31:2476-2488.
103. Nieweg K., Schaller H., Pfrieger F.W. Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J Neurochem 2009, 109:125-134.
104. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
105. Orr H.T., Zoghbi H.Y. Trinucleotide repeat disorders. Annu Rev Neurosci 2007, 30:575-621.
106. Paulsen J.S., Magnotta V.A., Mikos A.E., Paulson H.L., Penziner E., Andreasen N.C., et al. Brain structure in preclinical Huntington's disease. Biol Psychiatry 2006, 59:57-63.
107. Paulson H.L., Fischbeck K.H. Trinucleotide repeats in neurogenetic disorders. Annu Rev Neurosci 1996, 19:79-107.
108. Pehar M., Cassina P., Vargas M.R., Castellanos R., Viera L., Beckman J.S., et al. Astrocytic production of nerve growth factor in motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J Neurochem 2004, 89:464-473.
109. Pekny M., Nilsson M. Astrocyte activation and reactive gliosis. Glia 2005, 50:427-434.
110. Peleshok J., Saragovi H.U. Functional mimetics of neurotrophins and their receptors. Biochem Soc Trans 2006, 34:612-617.
111. Pfrieger F.W. Roles of glial cells in synapse development. Cell Mol Life Sci 2009, 66:2037-2047.
112. Pfrieger F.W., Barres B.A. New views on synapse-glia interactions. Curr Opin Neurobiol 1996, 6:615-621.
113. Raghavendra V., Rutkowski M.D., De Leo J.A. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci 2002, 22:9980-9989.
114. Ransohoff R.M., Perry V.H. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009, 27:119-145.
115. Reichardt L.F. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006, 361:1545-1564.
116. Rogers J., Kirby L.C., Hempelman S.R., Berry D.L., McGeer P.L., Kaszniak A.W., et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993, 43:1609-1611.
117. Rossi D., Volterra A. Astrocytic dysfunction: insights on the role in neurodegeneration. Brain Res Bull 2009, 80:224-232.
118. Rothstein J.D., Martin L., Levey A.I., Dykes-Hoberg M., Jin L., Wu D., et al. Localization of neuronal and glial glutamate transporters. Neuron 1994, 13:713-725.
119. Rothstein J.D., Dykes-Hoberg M., Pardo C.A., Bristol L.A., Jin L., Kuncl R.W., et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996, 16:675-686.
120. Saijo K., Winner B., Carson T.C., Collier J.G., Boyer L., Rosenfeld M.G., et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009, 137:47-59.
121. Schols L., Bauer P., Schmidt T., Schulte T., Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 2004, 3:291-304.
122. Serbest G., Burkhardt M.F., Siman R., Raghupathi R., Saatman K.E. Temporal profiles of cytoskeletal protein loss following traumatic axonal injury in mice. Neurochem Res 2007, 32:2006-2014.
123. Servadio A., Koshy B., Armstrong D., Antalffy B., Orr H.T., Zoghbi H.Y. Expression analysis of the ataxin-1 protein in tissues from normal and spinocerebellar ataxia type 1 individuals. Nat Genet 1995, 10:94-98.
124. Sheldon A.L., Robinson M.B. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int 2007, 51:333-355.
125. Shi Z., Birman E., Saragovi H.U. Neurotrophic rationale in glaucoma: a TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells in vivo. Dev Neurobiol 2007, 67:884-894.
126. Simard M., Nedergaard M. The neurobiology of glia in the context of water and ion homeostasis. Neuroscience 2004, 129:877-896.
127. Skaper S.D. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets 2008, 7:46-62.
128. Sposato V., Bucci M.G., Coassin M., Russo M.A., Lambiase A., Aloe L. Reduced NGF level and TrkA protein and TrkA gene expression in the optic nerve of rats with experimentally induced glaucoma. Neurosci Lett 2008, 446:20-24.
129. Sun W., Lin H., Chen B., Zhao W., Zhao Y., Xiao Z., et al. Collagen scaffolds loaded with collagen-binding NGF-beta accelerate ulcer healing. J Biomed Mater Res A 2010, 92:887-895.
130. Suzuki A., Stern S.A., Bozdagi O., Huntley G.W., Walker R.H., Magistretti P.J., et al. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 2011, 144:810-823.
131. Takano T., Tian G.F., Peng W., Lou N., Libionka W., Han X., et al. Astrocyte-mediated control of cerebral blood flow. Nat Neurosci 2006, 9:260-267.
132. Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010, 37:510-518.
133. Teng H.K., Teng K.K., Lee R., Wright S., Tevar S., Almeida R.D., et al. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci 2005, 25:5455-5463.
134. Trotti D., Aoki M., Pasinelli P., Berger U.V., Danbolt N.C., Brown R.H., et al. Amyotrophic lateral sclerosis-linked glutamate transporter mutant has impaired glutamate clearance capacity. J Biol Chem 2001, 276:576-582.
135. Tuszynski M.H., Thal L., Pay M., Salmon D.P., U H.S., Bakay R., et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005, 11:551-555.
136. Unger J.W. Glial reaction in aging and Alzheimer's disease. Microsc Res Tech 1998, 43:24-28.
137. van Noort J.M., van den Elsen P.J., van Horssen J., Geurts J.J., van der Valk P., Amor S. Preactive multiple sclerosis lesions offer novel clues for neuroprotective therapeutic strategies. CNS Neurol Disord Drug Targets 2011, 10:68-81.
138. Verkhratsky A., Olabarria M., Noristani H.N., Yeh C.Y., Rodriguez J.J. Astrocytes in Alzheimer's disease. Neurotherapeutics 2010, 7:399-412.
139. Vilar M., Murillo-Carretero M., Mira H., Magnusson K., Besset V., Ibáñez C.F. Bex1, a novel interactor of the p75 neurotrophin receptor, links neurotrophin signaling to the cell cycle. EMBO J 2006, 25:1219-1230.
140. Watkins L.R., Maier S.F. Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2003, 2:973-985.
141. Watkins L.R., Milligan E.D., Maier S.F. Glial activation: a driving force for pathological pain. Trends Neurosci 2001, 24:450-455.
142. Weickert C.S., Ligons D.L., Romanczyk T., Ungaro G., Hyde T.M., Herman M.M., et al. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2005, 10:637-650.
143. Wieseler-Frank J., Maier S.F., Watkins L.R. Glial activation and pathological pain. Neurochem Int 2004, 45:389-395.
144. Williams L.R., Varon S., Peterson G.M., Wictorin K., Fisher W., Bjorklund A., et al. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci USA 1986, 83:9231-9235.
145. Wong S.T., Henley J.R., Kanning K.C., Huang K.H., Bothwell M., Poo M.M. A p75(NTR) and Nogo receptor complex mediates repulsive signaling by myelin-associated glycoprotein. Nat Neurosci 2002, 5:1302-1308.
146. Yano H., Torkin R., Martin L.A., Chao M.V., Teng K.K. Proneurotrophin-3 is a neuronal apoptotic ligand: evidence for retrograde-directed cell killing. J Neurosci 2009, 29:14790-14802.
147. Ye Z.C., Wyeth M.S., Baltan-Tekkok S., Ransom B.R. Functional hemichannels in astrocytes: a novel mechanism of glutamate release. J Neurosci 2003, 23:3588-3596.
148. Zaccaro M.C., Lee H.B., Pattarawarapan M., Xia Z., Caron A., L'Heureux P.J., et al. Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities. Chem Biol 2005, 12:1015-1028.
149. Zhuang Z.Y., Gerner P., Woolf C.J., Ji R.R. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005, 114:149-159.